CEO, CFO, 10%
Snehal S. Patel is the Chief Executive Officer (CEO), Chief Financial Officer (CFO), Director, and a 10% owner of Greenwich LifeSciences, Inc. (GLSI), a clinical-stage biopharmaceutical company developing novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers.[[1]](https://www.stocktitan.net/sec-filings/GLSI/form-4-greenwich-life-sciences-inc-insider-trading-activity-2f5b41d4b369.html)[[2]](https://greenwichlifesciences.com/about/leadership/)[[5]](https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-glsi/greenwich-lifesciences/news/snehal-patel-buys-handful-of-shares-in-greenwich-lifescience) With over 30 years of experience in executive management, corporate development, operations, and investment banking in the healthcare and biotech sectors, Patel has consulted on R&D, manufacturing design, scale-up, and operations for multiple public and private biotech firms, including projects in stem cell therapy, multiple sclerosis T-cell therapy, oncolytic viruses, and disposable biotech manufacturing equipment.[[2]](https://greenwichlifesciences.com/about/leadership/)
Patel's career includes investment banking roles at Sanders Morris Harris, Ferghana Partners, and JP Morgan Chase, focusing on healthcare and biotech financing and strategic transactions, as well as prior positions in operations and business development at consulting firms and Bayer Corporation.[[2]](https://greenwichlifesciences.com/about/leadership/) He holds a BS in Chemical Engineering and an MS in Biochemical Engineering from the Massachusetts Institute of Technology (MIT), a Certificate in Project Management from the University of California at Berkeley, and an MBA from the University of Chicago.[[2]](https://greenwichlifesciences.com/about/leadership/) Recently, Patel has demonstrated confidence in GLSI by purchasing additional shares, including 2,900 shares on January 12, 2026, at $27.54 per share (bringing direct holdings to 5,602,302 shares), among other transactions in early 2026.[[1]](https://www.stocktitan.net/sec-filings/GLSI/form-4-greenwich-life-sciences-inc-insider-trading-activity-2f5b41d4b369.html)[[3]](https://www.investing.com/news/insider-trading-news/greenwich-lifesciences-ceo-patel-buys-53694-in-glsi-stock-93CH-4449080)
View full insider profile →
